The European Commission and EDCTP participating states have published an (informal) draft proposal for the EDCTP successor program, the EU-Africa health partnership. The EU–Africa Global Health Partnership –the third program of the European & Developing Countries Clinical Trials Partnership (EDCTP3)– will support international research partnerships accelerating the clinical evaluation of drugs, vaccines and diagnostics for key infectious diseases affecting sub-Saharan Africa, as well as novel approaches for surveillance and control of emerging/re-emerging infections. It will also strengthen clinical research capacity in the region. Building on the two previous EDCTP programs, the Partnership will ensure that more people gain access to new medical interventions and help to protect regional and global health security.
According to the proposal, the EU-Africa GH Partnership will address infectious diseases in sub-Saharan Africa by focusing on two main challenges (aligning with current scope of EDCTP):
- Lack of health technologies for tackling infectious diseases in sub-Saharan Africa, and
- Insufficient clinical research capacity for tackling infectious diseases in sub-Saharan Africa, and limited knowledge exchange and research collaboration.
It is mentioned that “in addition, to further leverage larger and sustained funding and to play a stronger global health leadership role than the current EDCTP2, the EDCTP3/EU-Africa Global Health Partnership will address emerging infectious diseases threats, exemplified by the COVID-19 pandemic, and the ever-increasing problem of antimicrobial resistance and non-communicable disease co-morbidities.” There is also an emphasis on regulatory strengthening.
EGHRIN will further assess the document in the coming days and considers an adaptation of its earlier position paper on this partnership.